Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation

Investigator Centers Will Be All French Hematology Centers Performing Autologous Transplantation and Prescribing Mozobil in Hematopoietic Stem Cell Mobilization Willing to Participate In This Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01738373

Enrollment

262

Registered

2012-11-30

Start date

2011-12-31

Completion date

2012-11-30

Last updated

2015-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Marrow / Autologous Transplants

Keywords

autologous stem cell transplantation, lymphoma, multiple myeloma

Brief summary

The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.

Interventions

DRUGPlerixafor

Plerixafor will be prescribed independently by the physician, according to usual practice.

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients treated with Plerixafor for autologous transplantation between November 2011 and November 2012 * Patients who have been informed and who have given their written consent for the access to their medical file

Exclusion criteria

* Patients already included in a Plerixafor ongoing clinical trial.

Design outcomes

Primary

Measure	Time frame
The characteristics of the patients who received treatment	13 months
Dosage of treatment	13 months
Number of CD34+ cells collected following treatment	13 months
Number of patients with the existence of one or more predictive factors of poor mobilisation	13 months
Duration of treatment	13 months
Associated treatments	13 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026